AZN•benzinga•
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
Summary
AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various SARS-CoV-2 variants.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2024 by benzinga